Exagen Inc. and Johns Hopkins University Partner to Develop Biomarkers Tests Lupus Nephritis Management
11-10-23 (by: Scott Gleason) Exagen has joined forces with Johns Hopkins University as the two entities jointly announced the execution of an exclusive license agreement designed to advance the development of novel patented biomarkers for lupus nephritis.
Under the terms of this exclusive agreement, Exagen is set to acquire a worldwide license to new biomarkers which it intends to incorporate into new diagnostic assays for lupus nephritis. These assays aim to provide clinical insights for the non-invasive assessment and management of the disease, ultimately contributing to enhanced diagnostic accuracy and treatment decision-making. Lupus nephritis is a debilitating condition resulting from the autoimmune disease systemic lupus erythematosus (SLE), which affects the kidneys and can lead to severe renal complications. Timely and precise diagnosis can lead to better outcomes. The licensed biomarkers have the potential to offer a non-invasive means of disease assessment. 1.5 million adults in the U.S. have a form of lupus and 50% will develop lupus nephritis.
John Aballi, President and CEO of Exagen Inc., expressed his enthusiasm about this promising collaboration and the potential it holds for advancing lupus nephritis patient care. “We are very excited to accelerate the development of these highly innovative biomarkers for lupus nephritis patient management. Exagen has a strong track record of serving clinicians in the autoimmune space, and having the opportunity to work with this exceptional team further reinforces our commitment to developing novel technology in this space.”